Cefotaxime

CHEMBL1730 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
455.5 g/mol
LogP
-1.4
Phase
4

A third-generation cephalosporin antibiotic with broad-spectrum activity against gram-negative bacteria and many gram-positive organisms, widely used for meningitis, sepsis, and serious respiratory and urinary tract infections. It penetrates the blood-brain barrier effectively, making it valuable in central nervous system infections. It is metabolized to desacetylcefotaxime, which retains some antibacterial activity.

น้ำหนักโมเลกุล

455.5000 g/mol

LogP

-1.40

TPSA

227.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1

InChI

InChI=1S/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9-/t10-,14-/m1/s1

Molecular Formula

C16H17N5O7S2

HBD / HBA

3 / 12

พันธะที่หมุนได้

8

อะตอมหนัก

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A third-generation cephalosporin antibiotic with broad-spectrum activity against gram-negative bacteria and many gram-positive organisms, widely used for meningitis, sepsis, and serious respiratory and urinary tract infections. It penetrates the blood-brain barrier effectively, making it valuable in central nervous system infections. It is metabolized to desacetylcefotaxime, which retains some antibacterial activity.

Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.

Yes, Cefotaxime is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1730. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5742673. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.